Ortho Panel Green Lights VertiFlex’s Superion Spine Spacer
This article was originally published in The Gray Sheet
A majority of FDA advisors say the device intended to treat lumbar spinal stenosis has a positive risk-benefit profile but should require an extended postmarket trial to evaluate its safety and efficacy over a longer time period.
You may also be interested in...
Minimally invasive interspinous spacer did not get the support of an FDA advisory panel in the face of serious questions about Medtronic's study design.
Medtronic gets February panel date for its DIAM spine device, which would be the firm's second interspinous spacer on the market; FDA moves risk classifications forward for five device types; and the agency continues its scrutiny of direct-to-consumer genetic tests.
St. Francis Medical Technologies will begin marketing the X-Stop non-fusion device for lumbar spinal stenosis in January to experienced surgeons in order to build the product's reputation